Navigation Links
Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
Date:10/3/2007

CAMBRIDGE, Mass., Oct. 3 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PI-2301, a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

The Phase I single ascending dose, double blind placebo controlled randomized study will involve 56 healthy male volunteers who will receive the drug in eight escalating dose cohorts. Following establishment of safety at potentially therapeutic doses, the Company will initiate its first repeat dose study in multiple sclerosis patients in early 2008.

PI-2301 is a second generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system to control the pathogenic autoimmune response in certain diseases. PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and in pre- clinical studies, has shown to be more potent and effective than Copaxone(R) in treating disease models for multiple sclerosis. PI-2301 has also shown efficacy in pre-clinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis and autoimmune uveitis. Peptimmune has also introduced highly reproducible manufacturing methods that allow very strict control and characterization of PI-2301 and should provide a superior level of batch to batch consistency.

"The commencement of this clinical trial is an important milestone for the development of PI-2301 and for the Company," stated Thomas Mathers, President and CEO of Peptimmune. "The goal for PI-2301 is to enhance the therapeutic benefit of a proven compound class in multiple sclerosis and give neurologists a new weapon as a primary treatment for patients with thi
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Malvern initiates European user group meetings for chemical imaging
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... Auf seiner am ... veranstalteten F&E-Tagung meldete Astellas Fortschritte im ... Forschungsrahmenprogramms. Die Tagung bot Astellas die Gelegenheit, ... Programme und die Konzernstrategie des Unternehmens zu ... aktuelle Meldungen zu den Astellas-Initiativen in den ...
(Date:7/13/2014)... , July 13, 2014  Eli Lilly ... announced results from its non-clinical study in genetically ... version of the beta-amyloid antibody N3pG and beta-secretase ... therapy was more effective in removing clumps of ... that is thought to lead to Alzheimer,s disease ...
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. ... vegetable-glycol solution for use in portable vaporizers, which ... active ingredients in cannabis, cannabidiol offers consumers a ... devices, and other vaporizer technology. Photo ... naturally contains 483 different compounds which are currently ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
... is,being released by The Philadelphia AIDS Consortium:, ... with its network of eleven (11) community-based organization,sites ... of 30 AmeriCorps ACTS members working throughout New,Jersey, ... 2008: 9 a.m. until Noon; Media Focused,Event 10:30 ...
... highlights:, In a small study, miniaturized heart pumps ... The devices are not approved for general use ... In a recent study, nine,pediatric patients with severe heart ... days with miniaturized heart assist pumps while,awaiting a heart ...
Cached Medicine Technology:Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures 2American Heart Association Journal Report: Miniaturized Heart Pumps May Be Effective for Children Awaiting Transplant 2
(Date:7/13/2014)... (PRWEB) July 13, 2014 MarketsandMarkets ... Market [3D Modeling; 3D Scanning; 3D rendering; Layout ... and Analysis (2013 - 2018)”, which analyzes and ... in North America, Western Europe, Eastern Europe, Middle ... report also draws the competitive landscape of the ...
(Date:7/13/2014)... Seattle, WA (PRWEB) July 13, 2014 ... a longer recovery period from concussions, according to research ... Medicine’s ( AOSSM ) Annual Meeting. The research marks ... to concussion based on the known physical events that ... that patients with a long allele in the (GT)n ...
(Date:7/13/2014)... July 13, 2014 Recently, MyDressCity.com, one ... women’s special occasion outfits, has released its new range ... the new products are available at discounted prices. Worldwide ... 2014. , In the company’s online shop, there ... of them are made with great materials. MyDressCity.com’s hot ...
(Date:7/13/2014)... decreased ability to identify odors might indicate the ... examinations of the eye could indicate the build-up ... the brain, according to the results of four ... International Conference 2014 (AAIC 2014) in Copenhagen. , ... to identify odors was significantly associated with loss ...
(Date:7/13/2014)... Celebrity fitness trainer and former World Super ... with Aqua Health Labs for their flagship product PhytOriginal, ... The collaboration was recently announced live on ESPN Radio. ... actor, model, and a two time World Super Middleweight ... has prepared stars including Demi Moore, Hilary Swank and ...
Breaking Medicine News(10 mins):Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
... Residents to Also Press For ... Immediate ... National House Call campaign visits New Mexico,today and urges residents to ... will slash physician payments 15,percent over the next two years. ...
... F. Murphy Appointed Director, First Ray and Stephanie ... Mellon University,announced today that it has received a ... establish the Ray and Stephanie Lane Center for,Computational ... and provide,support for doctoral and post-doctoral training in ...
... by German scientists may make blood doping and the ... hair. In the October print issue of The FASEB ... 100,000 hair follicles on each persons head have the ... primarily responsible for the creation of red blood cells, ...
... Position as the Global Leader in Endoscopic ... NDO Surgical, Inc. (NDO),announced that the ... the,Company,s Plicator II(TM) multiple implant technology for ... improved outcomes for,harder-to-treat gastroesophageal reflux disease (GERD) ...
... research that aligns patients and treatments., ... The,H. Lee Moffitt Cancer Center & ... health enterprise platform, to aid in its,development ... be used,to assimilate large quantities of diverse ...
... of Michigan has,received a national award for leadership excellence ... BCN received a DMAA Disease Management Leadership Award ... for Healthy Blue Living(SM),the innovative product BCN introduced in ... attempting to meet healthy lifestyle goals. "It is ...
Cached Medicine News:Health News:AMA Urges Congress to Stop Medicare Cuts 2Health News:Carnegie Mellon Establishes Ray and Stephanie Lane Center for Computational Biology 2Health News:Carnegie Mellon Establishes Ray and Stephanie Lane Center for Computational Biology 3Health News: New discovery leaves blood-doping athletes scratching their heads 2Health News:NDO Receives FDA 510(K) Clearance for Plicator II(TM) 2Health News:Moffitt Selects Microsoft's Azyxxi to Help Drive Personalized Cancer Treatment 2Health News:Blue Care Network of Michigan Earns National Leadership Award for Chronic Disease Management 2
Smooth pointed tips open to 3.0 mm. Cross action curved shafts. Tip to Angle Length: 12.0 mm. Round handle....
Straight, narrowed shafts with extra fine blunted tips. Smooth handle with dull finish....
Delicate cross serrated lightly curved tips with serrated handle and polished finish. Most popular size or model....
Fine pointed grooved jaws with smooth curve from tip to finger grip style handle. Dull finish....
Medicine Products: